[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Contribution
April 1998

Systemic Autoimmune Features and Multiple Sclerosis: A 5-Year Follow-up Study

Author Affiliations

From the Fédération de Neurologie and Université Paris VI (Drs Tourbah, Clapin, Gout, Fontaine, Liblau, Lubetzki, and Lyon-Caen), INSERM U134 et CJF Pathologie de la Myéline (Drs Tourbah, Fontaine, Liblau, and Lubetzki), and Laboratoire d'Immunologie Cellulaire (Dr Liblau), Hôpital de la Salpêtrière; Neuroradiology Department, Centre Hospitalier National d'Ophtalmologie des XV-XX (Drs Tourbah and Stiévenart); and Laboratoire d'Immunologie and Université Paris V, Hôpital Cochin (Drs Batteux and Weill), Paris, France.

Arch Neurol. 1998;55(4):517-521. doi:10.1001/archneur.55.4.517

Objectives  To evaluate in patients with multiple sclerosis (MS) the occurrence of clinical systemic signs and biological autoimmune abnormalities, including positive titers of antinuclear antibodies and antiphospholipid antibodies, suggestive of autoimmune diseases that may affect the central nervous system. Also, to compare the clinical and magnetic resonance imaging features and evolution of MS in patients with and without autoimmune abnormalities.

Design and Patients  Prospective study of 161 patients fulfilling the criteria of having probable or definite MS hospitalized in our institution between November 1990 and June 1992.

Results  Among the 161 patients, 84 (52.1%) had at least 1 clinical and/or biological general sign suggestive of an autoimmune disease; 64 were followed up for 4 to 5 years. The diagnosis of MS was confirmed in 50 patients and is still pending in 14 of them. No significant difference was found between patients with MS who were free of autoimmune features and those with autoimmune abnormalities (MS plus) concerning the age of disease onset, the presenting symptoms and signs, symptoms found on neurologic examination, and the course of the disease. For all patients with confirmed MS, general signs were found in 13.3%, positive titers of antinuclear antibodies in 26%, and positive titers of antiphospholipid antibodies in 6.2%.

Conclusions  Patients with MS with autoimmune features, including those with titers of antinuclear antibodies of 1:100 or less and/or antiphospholipid antibodies, are not different than others with MS, and therefore should not be excluded from clinical trials.